We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Stephen Sinclair

Stephen H Sinclair MD

CEO, Sinclair Technologies

After finishing medical school at Harvard, ophthalmology residency at Massachusetts Eye and Ear Infirmary, and a vitreo-retinal fellowship at the Medical College of Wisconsin, Dr. Sinclair spent 8 years as Assistant Professor of Ophthalmology and head of the vitreo-retinal service at the Hospital of the University of Pennsylvania in Philadelphia. He then migrated across town to Hahnemann University School of Medicine as Professor and of Ophthalmology to establish a new department as Chairman and then spent 6 years as vice-chairman of the Department. He left academia in 1993 and currently maintains a referral, private practice in vitreo-retinal diseases and surgery at in Media, Pennsylvania with affiliation at Riddle Memorial Hospital in the western and southwestern suburbs of Philadelphia. He remains as Adjunct Professor of Ophthalmology at Hahnemann, University teaching residents and students at Hahnemann and Temple Universities and at the Pennsylvania College of Optometry.

Disclosures

Dr. Sinclair is the CEO of Sinclair Technologies which has produced the FDA approved Central Vision Analyzer that is mentioned in the article and he is on the Board of Directors of the International Retinal Laser Society which is developing cooperative studies of the application of micropulse laser for diabetic retinopathy.